Topic: psoriatic arthritis
Think the success of several megablockbusters such as AbbVie’s Humira means the anti-inflammation market is fully saturated? Think again.
Pfizer totted up a list of accomplishments and milestones in 2018, besides the fact that it managed to eke out growth of about 2% for the year. It reorganized into three business units, for instance, reviving talk of an eventual generics spinoff and setting up its consumer health business for easier disposal.
Pfizer moved rheumatoid arthritis patients to a lower Xeljanz dose after a data monitoring board highlighted safety concerns for the 10-mg arm.
Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis.
Expanding Otezla's market to scalp psoriasis could be challenging for Celgene, in light of hurdles such as mounting competition.
As the psoriatic arthritis field heats up, Novartis has added some new data to its Cosentyx label it hopes can stretch out the drug’s lead.
With new nods for Pfizer’s Xeljanz and AbbVie’s upadacitinib coming, makers of anti-inflammatory drugs will be feeling the heat from JAK inhibitors.
In CEO David Ricks' first year running the show, Eli Lilly posted nearly 8% revenue growth to $22.87 billion, beating the high end of its own guidance of $22.7 billion set in the third-quarter report.
Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.